Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1960 1
1963 2
1964 1
1965 1
1966 5
1967 1
1968 1
1969 2
1970 2
1971 2
1972 2
1973 1
1976 2
1977 1
1978 1
1979 6
1980 3
1981 6
1982 2
1983 2
1984 5
1985 5
1986 4
1987 2
1988 4
1989 1
1990 1
1991 2
1992 2
1994 1
1996 1
1997 3
1998 1
1999 1
2000 5
2001 4
2002 8
2003 6
2004 9
2005 13
2006 14
2007 12
2008 4
2009 19
2010 29
2011 26
2012 29
2013 32
2014 35
2015 52
2016 36
2017 36
2018 27
2019 27
2020 44
2021 60
2022 56
2023 42
2024 43
2025 35

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

687 results

Results by year

Filters applied: . Clear all
Page 1
Allergic Contact Dermatitis.
Kostner L, Anzengruber F, Guillod C, Recher M, Schmid-Grendelmeier P, Navarini AA. Kostner L, et al. Immunol Allergy Clin North Am. 2017 Feb;37(1):141-152. doi: 10.1016/j.iac.2016.08.014. Immunol Allergy Clin North Am. 2017. PMID: 27886903 Free article. Review.
Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO.
Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C. Dumas PY, et al. Leukemia. 2023 Jan;37(1):91-101. doi: 10.1038/s41375-022-01742-7. Epub 2022 Nov 14. Leukemia. 2023. PMID: 36376378 Free article.
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
Harrison CN, Vannucchi AM, Recher C, Passamonti F, Gerds AT, Hernandez-Boluda JC, Yacoub A, Sirhan S, Ellis C, Patel B, Strouse B, Platzbecker U. Harrison CN, et al. Adv Ther. 2024 Sep;41(9):3722-3735. doi: 10.1007/s12325-024-02928-4. Epub 2024 Jul 11. Adv Ther. 2024. PMID: 38990433 Free PMC article. Clinical Trial.
The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia.
DiNardo CD, Pratz KW, Panayiotidis P, Wei X, Vorobyev V, Illés Á, Kim I, Ivanov V, Ku G, Miller CL, Zhang M, Tatsch F, Potluri J, Schmidt X, Récher C. DiNardo CD, et al. Am J Hematol. 2025 Jan;100(1):185-188. doi: 10.1002/ajh.27515. Epub 2024 Nov 1. Am J Hematol. 2025. PMID: 39487568 Free PMC article. No abstract available.
Circovirus Hepatitis in Immunocompromised Patient, Switzerland.
Hamelin B, Pérot P, Pichler I, Haslbauer JD, Hardy D, Hing D, Loulizi S, Regnault B, Pieters A, Heijnen I, Berkemeier C, Mancuso M, Kufner V, Willi N, Jamet A, Dheilly N, Eloit M, Recher M, Huber M, Mertz KD. Hamelin B, et al. Emerg Infect Dis. 2024 Oct;30(10):2140-2144. doi: 10.3201/eid3010.240678. Emerg Infect Dis. 2024. PMID: 39320240 Free PMC article.
NPM1: the ultimate target in AML.
Récher C. Récher C. Blood. 2025 Aug 28;146(9):1031-1032. doi: 10.1182/blood.2025029622. Blood. 2025. PMID: 40875551 No abstract available.
Immunologic and Genetic Contributors to CD46-Dependent Immune Dysregulation.
Meyer BJ, Kunz N, Seki S, Higgins R, Ghosh A, Hupfer R, Baldrich A, Hirsiger JR, Jauch AJ, Burgener AV, Lötscher J, Aschwanden M, Dickenmann M, Stegert M, Berger CT, Daikeler T, Heijnen I, Navarini AA, Rudin C, Yamamoto H, Kemper C, Hess C, Recher M. Meyer BJ, et al. J Clin Immunol. 2023 Nov;43(8):1840-1856. doi: 10.1007/s10875-023-01547-y. Epub 2023 Jul 21. J Clin Immunol. 2023. PMID: 37477760 Free PMC article.
CPX-351 in FLT3-mutated acute myeloid leukemia.
Andrews C, Pullarkat V, Recher C. Andrews C, et al. Front Oncol. 2023 Nov 17;13:1271722. doi: 10.3389/fonc.2023.1271722. eCollection 2023. Front Oncol. 2023. PMID: 38044999 Free PMC article. Review.
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment.
Garciaz S, Dumas PY, Bertoli S, Sallman DA, Decroocq J, Belhabri A, Orvain C, Aspas Requena G, Simand C, Laribi K, Carré M, Santagostino A, Himberlin C, Peterlin P, Bonnet S, Chan O, Lancet J, Komrokji R, Vergez F, Chapuis N, Raskovalova T, Plesa A, Lhoumeau AC, Mineur A, Hospital MA, Pigneux A, Vey N, Récher C. Garciaz S, et al. Am J Hematol. 2024 Oct;99(10):1870-1876. doi: 10.1002/ajh.27417. Epub 2024 Jun 20. Am J Hematol. 2024. PMID: 38899566
687 results